{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:59:17Z","timestamp":1790035157614,"version":"4.0.1"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,5,1]]},"DOI":"10.1001\/jamaoncol.2017.3361","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T17:35:12Z","timestamp":1512668112000},"page":"702","source":"Crossref","is-referenced-by-count":41,"title":["Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure"],"prefix":"10.1001","volume":"4","author":[{"given":"Susan","family":"Slovin","sequence":"first","affiliation":[{"name":"Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Clark","sequence":"additional","affiliation":[{"name":"Alaska Clinical Research Center, Anchorage"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Krivoshik","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Wook","family":"Park","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong","family":"Wang","sequence":"additional","affiliation":[{"name":"Medivation, Inc (acquired by Pfizer, Inc in September 2016), San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"George","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology, Duke Cancer Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2017.3361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T16:33:00Z","timestamp":1525969980000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2017.3361"}},"subtitle":["The UPWARD Study"],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2017.3361","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,1]]}}}